Abstract

Low-stress methods for controlling the movement of fish and/or shellfish by using light are known, but it has proven difficult to move many fish in a short period via conventional methods using only repellent colors and attractive colors. Provided is a method for facilitating the behavior control of fish and/or shellfish, said method being characterized in that in a holding space in which a region to which fish and/or shellfish are to be guided and a region other than said region to which fish and/or shellfish are to be guided have been established, the region other than said region to which fish and/or shellfish are to be guided is irradiated with a light spot having a size equal to or larger than the size of the fish and/or shellfish. Said method controls fish and/or shellfish not only by means of repellent colors and attractive colors, but also by means of a light spot having a size equal to or larger than the size of the fish and/or shellfish. By randomly moving the light spot toward the region to which fish and/or shellfish are to be guided or the region other than said region to which fish and/or shellfish are to be guided, the fish and/or shellfish can be moved in a short period.

IPC Classes  ?

• A01K 61/90 - Sorting, grading, counting or marking live aquatic animals, e.g. sex determination
• A01K 63/06 - Arrangements for heating or lighting in, or attached to, receptacles for live fish

Abstract

Provided is a novel method for producing phosphoric acid using sludge, human waste, or a processed product thereof as a raw material. A production method according to the present disclosure comprises: a step S11 for bringing a raw material into contact, in a solution, with a substance containing an anion capable of dissolving a sparingly soluble phosphate and forming a sparingly soluble metal salt; and a step S12 for removing the sparingly soluble metal salt formed in step S11. The sparingly soluble phosphate in step S11 contains a metal cation contained in the sparingly soluble metal salt in step S12.

IPC Classes  ?

• C01B 25/222 - Preparation by reacting phosphate containing material with an acid, e.g. wet process with sulfuric acid, a mixture of acids mainly consisting of sulfuric acid or a mixture of compounds forming it in situ, e.g. a mixture of sulfur dioxide, water and oxygen

Abstract

Provided is a manufacturing method for a phosphoric acid–containing organic fertilizer which has bone tissue as a raw material. The manufacturing method of the present disclosure comprises: step S21, a step for putting bone tissue, and a substance including an anion which can form a sparingly soluble calcium salt, in contact in a solution; and step S22, a step for removing the sparingly soluble calcium salt formed in step S21. The substance including an anion which can form a sparingly soluble calcium salt is a sulfate, tartaric acid, a tartrate, citric acid, a citrate, maleic acid, a maleate, malic acid, a malate, or an arbitrary combination of these.

IPC Classes  ?

• C05F 1/00 - Fertilisers made from animal corpses, or parts thereof
• A01G 7/00 - Botany in general

Abstract

Provided is a method for producing a biostimulant using a bone tissue as a raw material. A first production method according to the present disclosure comprises: step S11, in which a bone tissue is brought into contact, in a solution, with a substance containing an anion capable of forming a poorly soluble calcium salt; step S12, in which the poorly soluble calcium salt formed in the step S11 is removed; step S13, in which the solution obtained in the step S12 is brought into contact with a substance containing a cation capable of forming a poorly soluble phosphoric acid salt; and step S14, in which the poorly soluble phosphoric acid salt formed in the step S13 is removed. A second production method according to the present disclosure comprises: step S15, in which a bone tissue is brought into contact with a strong acid; step S16, in which the solution obtained in the step S15 is brought into contact with a base; and step S17, in which the poorly soluble phosphoric acid salt formed in the step S16 is removed.

IPC Classes  ?

• C05F 1/00 - Fertilisers made from animal corpses, or parts thereof
• A01G 7/00 - Botany in general

Abstract

Provided is a novel means that makes it possible to easily synthesize an oligosaccharide containing galactose with a β1-3 glycosidic bond. The present invention provides a method for synthesizing an oligosaccharide containing galactose with a β1-3 glycosidic bond (Galβ1-3 bond), the method comprising a step for bringing Gal-β-DMT (4,6-dimethoxy-1,3,5-triazin-2-yl β-D-galactopyranoside) serving as a sugar donor into contact with (I) a sugar-containing compound represented by formula (1) or (II) an oligosaccharide serving as a sugar receptor in the presence of β-1,3-galactosidase. [In formula (1), the ring A represents a residue of a monosaccharide or an oligosaccharide, the group X represents an aromatic compound group having an aromatic hydrocarbon ring skeleton or a heterocyclic skeleton, n indicates the number of the groups X, n is 1, and the residue is bonded to the group X as a result of one hydroxy group constituting the monosaccharide or the oligosaccharide being substituted or modified with the group X.]

IPC Classes  ?

• C12N 9/38 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-galactose-glycoside bonds, e.g. beta-galactosidase
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• C12P 19/00 - Preparation of compounds containing saccharide radicals

Abstract

It is known that phytol contained in a watermelon sprout has a cancer cell growth-inhibiting effect. However, a major limitation is that a relatively high dose is required to achieve this effect. A cancer cell growth-inhibiting composition comprising, as an active ingredient, at least one compound having a structure represented by formula (123), or a pharmaceutically acceptable salt thereof, exhibit a stronger inhibitory effect on cancer cell proliferation and a lower inhibitory effect on normal cell growth compared to phytol. Therefore, it may serve as an anticancer agent with excellent selectivity toward cancer cells. It is known that phytol contained in a watermelon sprout has a cancer cell growth-inhibiting effect. However, a major limitation is that a relatively high dose is required to achieve this effect. A cancer cell growth-inhibiting composition comprising, as an active ingredient, at least one compound having a structure represented by formula (123), or a pharmaceutically acceptable salt thereof, exhibit a stronger inhibitory effect on cancer cell proliferation and a lower inhibitory effect on normal cell growth compared to phytol. Therefore, it may serve as an anticancer agent with excellent selectivity toward cancer cells.

IPC Classes  ?

• C07C 381/12 - Sulfonium compounds
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61P 35/00 - Antineoplastic agents
• C07C 317/08 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton

Abstract

A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (9), formula (10), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

IPC Classes  ?

• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 311/86 - Oxygen atoms, e.g. xanthones

Abstract

The present invention addresses a problem in which a metal is easily corroded by rust when water is used as a plasma confinement layer in a laser peening method utilized as a metal surface modification method.　This laser processing method comprises a step of applying or affixing a gel-like substance to a processing region of an object to be processed, and a step of repeatedly irradiating the processing region with a laser. Because the laser processing method allows use of a gel-like substance containing no water as the plasma confinement layer, corrosion of the metal, which is the object to be processed, due to rust can be avoided. The gel-like substance is suitably used as a physical gel.

IPC Classes  ?

• B23K 26/356 - Working by laser beam, e.g. welding, cutting or boring for surface treatment by shock processing

Abstract

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. A compound represented by formula (11) has an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

IPC Classes  ?

• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 311/86 - Oxygen atoms, e.g. xanthones

Abstract

Air actuators contract and extend through intake and exhaustion of air, but since the air is exhausted only by internal pressure, air exhaustion takes longer than air intake, and high-speed contraction and extension operation cannot be performed.　The present invention addresses this problem by providing an air actuator including: a cylindrical frame in which a stopper is provided on an inner wall on one end side and the other end side is closed by a closing lid; a bag-shaped elastic body having a bag opening which is fixed to an end portion on the one end side of the cylindrical frame; an end pin which is disposed in the cylindrical frame, has a surface on the bag-shaped elastic body side and a surface on the closing lid side, is provided with a through-hole penetrating through the surface on the bag-shaped elastic body side and the surface on the closing lid side, and a gauge valve on the surface side on the bag-shaped elastic body side of the through-hole, the end pin being movable inside the cylindrical frame; an air passage which is provided in a side surface of the cylindrical frame and which is closed when the end pin abuts the stopper; and an air intake/exhaust pipe which is provided in the closing lid and which provides communication between the inside and the outside of the cylindrical frame. The air actuator can perform exhaust at once, and has excellent high-speed response.

IPC Classes  ?

• B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewingSafety devices combined with or specially adapted for use in connection with manipulators
• F15B 15/10 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type

Abstract

Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A pharmaceutical composition for preventing an aortic aneurysm is provided including a medium chain fatty acid as a main component, which has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers

Abstract

The present invention makes it possible to easily produce tomatine and obtain tomato residua at low cost from discarded tomato residua. This production method for a tomatine-containing extraction liquid uses the portion of tomato plants that is not the fruit as starting tomato residua and includes a step for estimating the water content and the dry weight of the starting tomato residua and a step for immersing the starting tomato residua in a starting extraction liquid that has a ratio of ethanol and acetic acid of 380:1 and has been prepared such that the abovementioned water content is 4%–6% of the whole. Repeating the steps makes it possible to increase the tomatine concentration of a tomatine-containing extraction liquid, and the water of the tomato residua is replaced with ethanol during the extraction, making it possible to obtain tomato residua by leaving to dry for about 24 hours.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A01N 45/00 - Biocides, pest repellants or attractants, or plant growth regulators containing compounds having three or more carbocyclic rings condensed among themselves, at least one ring not being a six-membered ring
• A01P 17/00 - Pest repellants
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Abstract

Antibody drugs have been proposed to treat allergic diseases, but the route of administration is limited to intravenous route, which is inconvenient for patients. In addition, novel agents that inhibit kinases such as NIK are always needed to develop effective drugs and other products to treat allergic diseases. At least one compound selected from mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) having a xanthone structure can improve allergic diseases and can be effective when taken orally. Antibody drugs have been proposed to treat allergic diseases, but the route of administration is limited to intravenous route, which is inconvenient for patients. In addition, novel agents that inhibit kinases such as NIK are always needed to develop effective drugs and other products to treat allergic diseases. At least one compound selected from mangiferin 8a (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthohydrol (formula (5)), α-mangostin (formula (6)), and γ-mangostin (formula (7)) having a xanthone structure can improve allergic diseases and can be effective when taken orally.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 11/06 - Antiasthmatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 37/08 - Antiallergic agents

Abstract

Provided is a pharmaceutical composition including CADM1 antibodies or antigen-binding fragments thereof. A pharmaceutical composition of the present disclosure for use in the treatment of CADM1-related diseases includes antibodies against CADM1 or antigen-binding fragments thereof.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 17/04 - Antipruritics
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 37/08 - Antiallergic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/13 - Immunoglobulins

Abstract

Provided is a novel anti-CADM1 antibody or an antigen-binding fragment thereof. An anti-CADM1 antibody or antigen-binding fragment thereof according to the present disclosure binds to an epitope comprising amino acid residues at positions 311, 325 and 326 in cell adhesion molecule 1 (CADM1).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C12N 15/13 - Immunoglobulins
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The purpose of the present invention is to provide a plant-derived beta-caryophyllene composition that includes plant-derived beta-caryophyllene and has excellent palatability, and from which a variety of safe products can be obtained, as well as a method for producing the same. In this composition including plant-derived beta-caryophyllene, the plant-derived beta-caryophyllene content is 80 wt% or greater, the eugenol content is 0.0455 wt% or less, and the methyl eugenol content is 0.005 wt% or less.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 36/61 - Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• C11B 9/00 - Essential oilsPerfumes
• C11B 9/02 - Recovery or refining of essential oils from raw materials

Abstract

Although it is desirable to perform imaging after knowing the state of respiration during X-ray testing, such imaging has not been carried out in actual medical sites at present. In addition, since the respiration state and information indicating under what respiration state the testing has been performed have not been stored along with a testing image, it had not been clear how much the respiration state has an effect on the test result during imaging. This X-ray imaging apparatus comprises: an X-ray imaging unit; a millimeter wave radar that irradiates a subject; a display unit that displays an X-ray image obtained by the X-ray imaging unit; and a control unit that displays, on the display unit, an output provided by the millimeter wave radar and a shutter time of the X-ray imaging unit. The X-ray imaging apparatus, by recording the state at the time of imaging instead of suppressing the movement of the body of the subject at the time of imaging, increases reproducibility, eliminates an increase in exposure amount due to re-testing, and provides great additional material when interpreting images.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing
• A61B 6/46 - Arrangements for interfacing with the operator or the patient

Abstract

The brain is slightly off-centered within the skull. In addition, current patient immobilization implements do not provide sufficient position (posture) reproducibility, and aligning a device in order to accurately irradiate a treatment target site in the brain takes a long time.　A subject positioning method according to the present invention includes: a step for obtaining a treatment planning image of a subject immobilized relative to a reference plane in order to make a treatment plan for the subject; a step for obtaining a pre-treatment image of the subject immobilized relative to the reference plane immediately prior to treatment of the subject; a step for determining a posture correction value with which the cerebral sulci in the treatment planning image and the cerebral sulci in the pre-treatment image can be made to overlap; and a step for correcting the posture of the subject during treatment on the basis of the posture correction value. In the subject positioning method, the cerebral sulci in the treatment planning image and the pre-treatment image are adjusted to coincide with each other, whereby radiation can be accurately applied to the treatment target site.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Disclosed is a kit for detecting a detection target substance, said kit comprising: a plasmon resonance chip; a first protein that specifically binds to the detection target substance; and a second protein that specifically binds to the detection target substance, wherein the plasmon resonance chip is provided with a substrate, a metallic particle aggregate layer that is formed on the substrate, and a protective layer that covers the metallic particle aggregate layer. Also disclosed is a detection method for a detection target substance which uses said kit.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The purpose is to detect at high sensitivity patients having a high risk of postoperative recurrence based on an expression profile of RNA extracted from platelets collected from cancer patients. To this end, a first expression profile, which is an expression profile of RNA extracted from platelets collected from the postoperative blood of a subject, is compared with cancer sufferer group expression profile, which is a set of expression profiles of RNA extracted from platelets collected from the blood of cancer sufferers belonging to the cancer sufferer group, and a non-cancer sufferer group expression profile, which is a set of expression profiles of RNA extracted from platelets collected from the blood of non-cancer sufferers belonging to the non-cancer sufferer group, and which of the expression profiles the first expression profile is similar to is determined.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Abstract

McKibben-type pneumatic rubber artificial muscles are known as soft actuators for use in robot devices. However, the McKibben-type pneumatic rubber artificial muscles require a pneumatic supply system, which poses a problem for miniaturization.　This artificial muscle includes a cylindrical braided tube that has side surfaces equidistant from a central axis formed by braiding fibers, end securing parts for securing both ends of the braided tube, respectively, a motor that has a drive shaft connected to one of the end securing parts in alignment with the central axis, and a drive control part for driving the motor, the artificial muscle being lightweight, not bulky, and can be suitably used in a wearable environment.

IPC Classes  ?

• F03G 7/00 - Mechanical-power-producing mechanisms, not otherwise provided for or using energy sources not otherwise provided for
• B25J 19/00 - Accessories fitted to manipulators, e.g. for monitoring, for viewingSafety devices combined with or specially adapted for use in connection with manipulators
• F15B 15/10 - Fluid-actuated devices for displacing a member from one position to anotherGearing associated therewith characterised by the construction of the motor unit the motor being of diaphragm type

Abstract

The present invention addresses the problem of providing: a novel compound; and a use of the compound.　The features of the present invention for solving the problem are as follows. 1. A compound represented by chemical formula (1). 2. A compound represented by chemical formula (2). 3. A transepidermal water loss reducing agent containing the compound mentioned in 1 or 2 as an active ingredient. 4. A moisturizing agent containing the compound mentioned in 1 or 2 as an active ingredient. 5. An agent for promoting the production of interleukin-6 in dendritic cells, which contains the compound mentioned in 1 or 2 as an active ingredient. 6. An immunostimulant containing the compound mentioned in 1 or 2 as an active ingredient. 7. A method for producing the compound mentioned in 1 or 2, the method being characterized by including a step for isolating the compound from an extract from rice bran.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
• A23G 3/36 - Sweetmeats, confectionery or marzipanProcesses for the preparation thereof characterised by the composition
• A23G 4/06 - Chewing gum characterised by the composition
• A23L 29/281 - Proteins, e.g. gelatin or collagen
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/06 - Emulsions
• A61K 8/68 - Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 9/06 - OintmentsBases therefor
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical

Abstract

Provided is a production method for producing a novel fertilizer (e.g., liquid fertilizer) containing a bone tissue degradation product. A production method for producing a fertilizer containing phosphoric acid in accordance with the present disclosure includes at least one of: a step 1 (S7) of producing a fertilizer from a bone solubilization liquid A which has been obtained by treating bone tissue with a solution containing both an acid and a protease; a step 2 (S2) of producing a fertilizer from an acid extract which has been obtained by treating bone tissue with an acid; and a step 3 (S5) of producing a fertilizer from a protease treatment liquid which has been obtained by treating, with a protease, bone tissue which has been treated with an acid.

IPC Classes  ?

• C05F 1/00 - Fertilisers made from animal corpses, or parts thereof
• C01B 25/22 - Preparation by reacting phosphate containing material with an acid, e.g. wet process
• C05B 11/06 - Fertilisers produced by wet-treating or leaching raw materials either with acids in such amounts and concentrations as to yield solutions followed by neutralisation, or with alkaline lyes using mineral acid using nitric acid (nitrophosphates)
• C05B 11/08 - Fertilisers produced by wet-treating or leaching raw materials either with acids in such amounts and concentrations as to yield solutions followed by neutralisation, or with alkaline lyes using mineral acid using sulfuric acid
• C05B 11/12 - Fertilisers produced by wet-treating or leaching raw materials either with acids in such amounts and concentrations as to yield solutions followed by neutralisation, or with alkaline lyes using mineral acid using aqueous hydrochloric acid
• C05B 17/00 - Other phosphatic fertilisers, e.g. soft rock phosphates, bone meal
• C05F 17/20 - Preparation of fertilisers characterised by biological or biochemical treatment steps, e.g. composting or fermentation using specific microorganisms or substances, e.g. enzymes, for activating or stimulating the treatment

Abstract

Provided is a fish in which accumulation of inosinic acid is enhanced or accelerated during ripening. In a fish of the present disclosure, the function of the ecto-5′-nucleotidase (nt5e) gene is lost.

IPC Classes  ?

• A01K 67/0276 - Knock-out vertebrates
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)

Abstract

Provided is a novel method for producing phosphoric acid. A production method for producing phosphoric acid in accordance with the present disclosure includes: a step (a) of obtaining an acid extract by treating bone tissue with an acid; a step (b) of obtaining a calcium phosphate precipitate by adding a base to the acid extract which has been obtained; a step (c) of obtaining a calcium phosphate solution by adding an acid to the calcium phosphate precipitate which has been obtained; and a step (d) of removing precipitated calcium by adding, to the calcium phosphate solution which has been obtained, at least one selected from the group consisting of sulfate, carbonate, and hydrogen carbonate.

IPC Classes  ?

• C01B 25/22 - Preparation by reacting phosphate containing material with an acid, e.g. wet process
• C05B 17/00 - Other phosphatic fertilisers, e.g. soft rock phosphates, bone meal
• C12N 9/50 - Proteinases

Abstract

Provided is a new method for producing phosphoric acid. A method for producing phosphoric acid according to the present disclosure comprises the following steps. Step S20: A step for treating, with an acid, a raw material containing calcium phosphate to obtain an acid extracted solution. Step S30: A step for mixing the obtained acid extracted solution with a base to obtain a calcium phosphate precipitate. Step S40: A step for mixing the obtained calcium phosphate precipitate with an acid and/or a salt thereof and forming a hardly soluble calcium salt.

IPC Classes  ?

• C01B 25/22 - Preparation by reacting phosphate containing material with an acid, e.g. wet process

Abstract

Provided is a novel method for producing a calcium salt. A method for producing a calcium salt according to one embodiment of the present disclosure has the following steps. Step S20: A step for acid-treating a raw material containing calcium phosphate to obtain an acid extract. Step S30: A step for mixing the resulting acid extract with a base to obtain a calcium phosphate precipitate. Step S40: A step for mixing the resulting calcium phosphate precipitate with an acid and/or a salt thereof and forming a calcium salt.

IPC Classes  ?

• C01F 11/46 - Sulfates
• C01B 33/24 - Alkaline earth metal silicates
• C01F 11/48 - Sulfites
• C07C 51/41 - Preparation of salts of carboxylic acids by conversion of the acids or their salts into salts with the same carboxylic acid part
• C07C 59/10 - Polyhydroxy carboxylic acids

Abstract

Provided is a method for using a sample containing cells collected from a patient to discriminate, with high sensitivity and high accuracy, normal cells and abnormal cells contained in the sample. A sample containing cells collected from a patient is irradiated with electromagnetic waves, an electromagnetic wave scattering spectrum from the cells in the sample is measured, and normal cells and abnormal cells are discriminated on the basis of the characteristics of the electromagnetic wave scattering spectrum. The discrimination uses a trained model in which the electromagnetic wave scattering spectra of normal cells and abnormal cells are trained. The sample may be a living cell, or may be a sample that is immobilized by an alcohol or formalin and dyed. The electromagnetic wave scattering spectrum may use either or both of a scattering spectrum obtained through Rayleigh scattering and a scattering spectrum obtained through Mie scattering.

IPC Classes  ?

• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/483 - Physical analysis of biological material

Abstract

Provided is a serum-free medium that is composed of a fewer number of constituent components and is less expensive.　The serum-free medium comprises Dulbecco's modified Eagle's medium (DMEM), albumin (BSA), and insulin-transferrin-selenium-ethanolamine (ITS-X). The serum-free medium is suitable for the culturing of mouse ES cells that are naïve pluripotent stem cells, and bears comparison with the most superior medium on the market.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor

Abstract

A determination method for a psychiatric disorder includes: acquiring a first reference value, a second reference value, a first comparison value, and a second comparison value, the first reference value being a heart rate variability index of a healthy person under a first sound stimulus environment, the second reference value being a heart rate variability index of the healthy person under a second sound stimulus environment different from the first sound stimulus environment, the first comparison value being a heart rate variability index of a user under the first sound stimulus environment, the second comparison value being a heart rate variability index of the user under the second sound stimulus environment; and executing comparison processing among the first reference value, the second reference value, the first comparison value, and the second comparison value to determine a possibility that the user has a psychiatric disorder.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/346 - Analysis of electrocardiograms

Abstract

In the treatment of cancer, although a molecular targeting agent is highly effective, the survival rate in advanced cancer accompanied by metastasis has not been improved. Therefore, it is an important problem to develop an antitumor drug that is effective against metastatic cancer.　This anticancer agent containing a squeezed tea fruit residue extract as an active ingredient is capable of suppressing the proliferation of cancer cells, capable of suppressing migration of cells, and capable of effectively suppressing cancer progression.

IPC Classes  ?

• A61K 36/82 - Theaceae (Tea family), e.g. camellia
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

It has been reported that acyldepsipeptides (ADEPs) disrupt intracellular protein degradation system complexes so as to exhibit strong antibacterial activities against various pathogenic bacteria including drug-resistant bacteria. In practice, however, it is hard to say that the antibacterial activities are sufficient.　It has been confirmed that various cyclic peptide compounds represented by formula (1) according to the present invention exhibit extremely high antibacterial activities compared with ADEP1 and the like.

IPC Classes  ?

• C07K 7/54 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
• A61K 38/15 - DepsipeptidesDerivatives thereof
• A61P 31/04 - Antibacterial agents
• C07B 61/00 - Other general methods

Abstract

An optical fiber output light source device includes an optical path that is obtained by joining a polarization maintaining amplifying optical fiber to a polarization maintaining dispersion compensating fiber, a single-polarization reflective polarizing beam splitter that is joined to one end of the optical path, a 90° polarization-rotating reflector that is joined to the other end of the optical path, a multiplexer that is inserted in the optical path, and a pumping light source that is joined to the multiplexer. An axis roll connection portion is provided in which a polarization axis of light returned from the single-polarization reflective polarizing beam splitter to the optical path is connected to a polarization maintaining axis of the optical path with a twisting angle therebetween at a predetermined angle.

IPC Classes  ?

• H01S 3/10 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating
• G02B 27/28 - Optical systems or apparatus not provided for by any of the groups , for polarising
• G02F 1/383 - Non-linear optics for second-harmonic generation in an optical waveguide structure of the optical fibre type
• H01S 3/067 - Fibre lasers
• H01S 3/108 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity using non-linear optical devices, e.g. exhibiting Brillouin or Raman scattering

Abstract

Freedom from designated hazardous substances, etc., and good writing properties were demanded of skin markers for making a mark on human skin. This ink for a skin marker that comprises water, a film-forming agent made of a polymer emulsion having a Tg of -70 to 40°C, and a colorant, the materials other than water being only materials listed in the Japanese Standards of Quasi-drug Ingredients 2021, is a water-based composition. Starting with the polymer emulsion used as a film-forming agent, the materials other than water in the ink are made of only materials listed in the Japanese Standards of Quasi-drug Ingredients 2021; therefore, there are no effects on the human body even when used directly on the skin. In addition, a new pen tip can always be used in a writing instrument in which a pen tip impregnated with this ink for a skin marker is covered by a body and a tip cover with an unopened indication means, thereby contributing to infection prevention.

IPC Classes  ?

• C09D 11/16 - Writing inks
• B43K 8/02 - Pens with writing-points other than nibs or balls with writing-points comprising fibres, felt, or similar porous or capillary material
• B43K 27/08 - Combinations of pens

Abstract

A method of treating short tear breakup time-type dry eye, including a step of administering, to a mammal including a human, (i) a copolymer (P) having three kinds of different constituent units represented by formulae (1a) to (1c) and a weight-average molecular weight of from 5,000 to 2,000,000, wherein a molar ratio among the constituent units [(1a)/(1b)/(1c)] in the copolymer (P) is 100/from 10 to 400/from 2 to 50, or (ii) a composition containing the copolymer (P) at a concentration of from 0.001 w/v % to 1.0 w/v %: 6 are as defined herein.

IPC Classes  ?

• A61K 31/80 - Polymers containing hetero atoms not provided for in groups
• A61K 9/08 - Solutions
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

A skeletal structure for an artificial pinna includes a base portion formed in a flat shape with a fibrous structural body using a bioabsorbable material, and a helix portion and an antihelix portion disposed on the front surface of the base portion. In the skeletal structure, the base portion is provided with a two-dimensional elastic structure, and the helix portion and the antihelix portion are provided with a three-dimensional fiber structure formed with the fibrous structural bodies. Thus, a flexible skeletal structure can be provided.

IPC Classes  ?

• A61L 27/58 - Materials at least partially resorbable by the body
• A61F 2/50 - Prostheses not implantable in the body
• A61L 27/38 - Animal cells

Abstract

The present invention provides a compound of formula (I): The present invention provides a compound of formula (I): wherein R1, R2, R3, R4, k, l, m and n are as defined in the specification, or a pharmaceutically acceptable salt thereof with the effect of inhibiting T-type calcium channels and a medicament useful for the treatment of a disease associated with the activation of T-type calcium channels.

IPC Classes  ?

• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• C07D 235/26 - Oxygen atoms

Abstract

It is known that phytol contained in watermelon sprouts has a cancer cell growth inhibiting effect. However, there is a problem that the amount to be ingested for exerting a cancer cell growth inhibiting effect is large.　A cancer cell growth inhibiting composition containing at least one component selected from a compound having a structure represented by formula (123) and pharmaceutically acceptable salts thereof as an active ingredient has a higher cancer cell growth inhibiting effect and a lower normal cell growth inhibiting effect than those of phytol and therefore can be used as an anticancer agent having excellent selectivity to cancer cells. R represents a C1-C3 alkyl group.

IPC Classes  ?

• C07C 381/12 - Sulfonium compounds
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/10 - SulfidesSulfoxidesSulfones
• A61P 35/00 - Antineoplastic agents
• C07C 317/08 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton

Abstract

The purpose of the present invention is to produce a polyamine in the intestines using an oral agent.　An enteral polyamine production agent according to the present invention comprises: a bean-derived digestion-resistant peptide comprising a protein component comprising a bean protein material and a degradation residue obtained by the degradation with a degrading enzyme; and a lactic acid bacterium capable of degrading agmatine into putrescine.

IPC Classes  ?

• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/18 - PeptidesProtein hydrolysates
• A23L 33/185 - Vegetable proteins
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell. Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell. A cancer cell growth-inhibiting composition including a substance having structures represented by formulas (1) to (6) has a higher antiproliferative effect on cancer cell than phytol by order of one or more magnitudes. Further, it is expected that these substances do not affect normal cells similarly to phytol. Thus, they are expected to provide an anticancer drug with less side effects. Phytol contained in watermelon sprouts is known to have an antiproliferative effect on cancer cell. However, there has been a problem in that a high dose is required to exert the antiproliferative effect on cancer cell. A cancer cell growth-inhibiting composition including a substance having structures represented by formulas (1) to (6) has a higher antiproliferative effect on cancer cell than phytol by order of one or more magnitudes. Further, it is expected that these substances do not affect normal cells similarly to phytol. Thus, they are expected to provide an anticancer drug with less side effects.

IPC Classes  ?

• A61K 31/131 - Amines, e.g. amantadine acyclic
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 35/00 - Antineoplastic agents

Abstract

According to one embodiment, a mammography apparatus includes processing circuitry. The processing circuitry is configured to acquire, as information on preliminary X-ray imaging for a breast of a subject, first information including at least one of an imaging condition, breast state information indicating a state of the breast, and/or information on the subject. The processing circuitry is configured to calculate an index for the breast based on the first information.

IPC Classes  ?

• A61B 6/04 - Positioning of patientsTiltable beds or the like
• A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications

Abstract

To establish an unprecedented novel method for producing D-luciferin and a D-luciferin derivative without using expensive 2-cyano-6-hydroxybenzothiazole that is obtained by a multi-stage production process. In the method for producing D-luciferin and a D-luciferin derivative, the above object is achieved via a novel substituted diaminodithioether represented by the following formula (1): 3 or OH; and Y, Z and W are H or monovalent organic groups, which serves as a precursor.

IPC Classes  ?

• C07C 323/58 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
• C07C 319/20 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

12BB, and the zero-dispersion/dispersion-flattened photonic crystal fiber satisfying the conditions of expressions (1) through (3).

IPC Classes  ?

• G02B 6/02 - Optical fibres with cladding
• G02B 6/036 - Optical fibres with cladding core or cladding comprising multiple layers

Abstract

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

IPC Classes  ?

• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 311/86 - Oxygen atoms, e.g. xanthones

Abstract

[Problem] [Problem] COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death. [Problem] COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death. [Solution to Problem] [Problem] COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death. [Solution to Problem] Compounds represented by formulas (1) to (4) are effective when taken orally and can be expressed in smaller amounts than mangiferin. [Problem] COVID-19 caused by coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome with CAR (chimeric antigen receptor)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu arteritis, and other diseases, if severe, can cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory insufficiency, multi-organ failure, and other symptoms which are one of the causes of death. [Solution to Problem] Compounds represented by formulas (1) to (4) are effective when taken orally and can be expressed in smaller amounts than mangiferin.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

This bolus, which is for radiation therapy, can be deformed to match the shape of a human body surface, and has little deformation during therapy. The bolus forming material is a rubber composition containing ethylene-propylene rubber and a temperature-sensitive material. The bolus forming material has a JIS type A hardness of 20 or higher at 30° C., and thus is not susceptible to deformation. The bolus forming material has a JIS type E hardness of 10 to 60 at 70° C., and thus easily deforms. The bolus forming material shifts the peak of the percentage depth dose for electron beams and X-rays in the beam source direction at 0.8 to 1.2 times the thickness thereof. Therefore, the bolus forming material has dose characteristics in the depth direction that are substantially the same as a human body. After a sheet of the bolus forming material is heated to around 70° C., the sheet deforms.

IPC Classes  ?

• C08L 23/16 - Ethene-propene or ethene-propene-diene copolymers
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• C08J 5/18 - Manufacture of films or sheets
• C08K 3/36 - Silica

Abstract

There are no drugs or food medicines that can prevent or ameliorate, among side effects caused by drugs, particularly peripheral neuropathy that is caused by anticancer drugs such as oxaliplatin. There are no drugs or food medicines that can prevent or ameliorate, among side effects caused by drugs, particularly peripheral neuropathy that is caused by anticancer drugs such as oxaliplatin. An agent for preventing or ameliorating peripheral neuropathy including at least one selected from xylitol, L-talitol, and D-threitol as an active ingredient can ameliorate tingling limbs, limb pain, decreased deep tendon reflexes, muscle weakness, allodynia, hyperalgesia, hand fine motor skill disability, gait disturbance, stumbling, falling, flexion impairment (difficulty or inability to sit on one's knees, cross-legged, sideways, in a chair, etc.), limb paralysis, or the like, induced by drugs such as anticancer drugs or diabetes.

IPC Classes  ?

• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

An easy-assembly bed includes a top plate, and a leg portion having a plurality of leg members that are linked using notched joints. The top plate is constituted of a bonded material, which includes a plate-shaped foam plate formed with a foam body, and a front board member and a rear board member having an identical shape to the foam plate and that are bonded to the rear surface and the front surface of the foam plate, respectively, and a top plate molded resin portion overing the cut ends of the bonded material with a molded resin; and the leg members are each constituted of a grooved bonded material, which includes a plate-shaped grooved foam plate having locking grooves and formed with a foam body, and a grooved front board member and a grooved rear board member on the front surface and the rear surface of the grooved foam plate.

IPC Classes  ?

• A47C 19/00 - Bedsteads
• A47B 96/20 - Furniture panels or like furniture elements
• A61G 7/05 - Parts, details or accessories of beds

Abstract

Provided is a novel antibody which may be used for the treatment of SARS-CoV-2.　An antibody or an antigen-binding fragment thereof according to the present disclosure is an anti-CADM1 antibody or an antigen-binding fragment thereof, wherein the antibody is selected from the group consisting of (Ca) and (Cb): (Ca) an antibody comprising the amino acid sequences of a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 represented by SEQ ID NOs:1, 2 and 3, respectively, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 represented by SEQ ID NOs:4, 5 and 6, respectively; and (Cb) a variant of (a) antibody including some of substitution, insertion, addition, or deletion in the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and/or the light chain CDR3.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• C07K 16/46 - Hybrid immunoglobulins
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low. The invention is also directed to methods of performing an ELISA, including sequential steps of contacting a solid surface with a plurality of solutions each comprising in turn a capture antibody, a blocking agent, a sample suspected of containing an analyte, a detection antibody and an enzyme conjugate, in which the solid surface is subjected to a wash process after each sequential step.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression. An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Antibody preparations for treating allergic diseases have been proposed. However, the route of administration of the antibody preparations is limited to an intravenous route, which imposes a burden on patients. Furthermore, novel drugs that inhibit kinases such as NIK are still needed for the development of effective pharmaceuticals and the like for treating allergic diseases.　At least one compound selected from mangiferin 8a having a xanthone backbone (formula (1)), norathyriol (formula (2)), mangiferin (formula (3)), 1,3,5,6-tetrahydroxyxanthone (formula (4)), xanthydrol (formula (5)), α-mangostin (formula (6)) and γ-mangostin (formula (7)) can ameliorate allergic diseases and can exhibit the effect thereof through oral ingestion.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 11/06 - Antiasthmatics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/04 - Antipruritics
• A61P 37/08 - Antiallergic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided are fish in which accumulation of inosinic acid is enhanced or accelerated during maturation.　The fish of the present disclosure have loss of function of the ecto-5'-nucleotidase (nt5e) gene.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 15/55 - Hydrolases (3)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A01K 67/02 - Breeding vertebrates
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

Antibody preparations for treating autoimmune-type diseases such as autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved have been proposed, but the administration route thereof has been limited to intravenous administration, which puts a burden on patients. Furthermore, novel medicines that inhibit kinases such as NIK are constantly needed for the development of effective drugs for treating autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved.　At least one compound selected from among yk-7 (formula (1)), yk-8-1, yk-8-3, M7, M9, M11, M12, M14, M15, M16, M18, and M19 having a xanthone skeleton can ameliorate autoimmune-type diseases and is capable of exhibiting an effect when taken orally.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 7/06 - Antianaemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/02 - Nasal agents, e.g. decongestants
• A61P 11/06 - Antiasthmatics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/06 - Antiabortive agentsLabour repressants
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/04 - Antipruritics
• A61P 17/06 - Antipsoriatics
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 27/16 - Otologicals
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 37/08 - Antiallergic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a composition for the treatment of vascular disease, for the prevention of vascular disease, for the treatment of hypertension or for the prevention of hypertension, comprising caryophyllene.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 8/31 - Hydrocarbons
• A61Q 19/00 - Preparations for care of the skin
• A61P 9/12 - Antihypertensives
• A24D 3/06 - Use of materials for tobacco smoke filters
• A24D 3/04 - Tobacco smoke filters characterised by their shape or structure
• A24D 3/14 - Use of materials for tobacco smoke filters of organic materials as additive

Abstract

Provided are an ocular surface drug-retaining agent that enables an excellent improvement in retainability of a medicament on an ocular surface and an eye drop containing the agent. An ocular surface drug-retaining agent containing a copolymer having three different kinds of constituent units at a specific ratio can express an excellent effect of retaining a medicament on an ocular surface (in particular, a corneal surface) to allow the effect or action of the drug to be sustained over a long period of time.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

A composition for treating or preventing respiratory diseases, a composition for improving sleep or promoting sleep onset, a composition for reducing fatigue, a composition for improving complexion, a composition for improving skin texture, a composition for treating or preventing periodontal disease, and a composition for controlling halitosis, each composition containing caryophyllene.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 8/31 - Hydrocarbons
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/20 - HypnoticsSedatives
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

In MRI, the current trend is for gantry magnetic fields to become increasingly stronger in order to enhance the detection accuracy. Thus, it is assumed that even objects referred to as non-magnetic, if electroconductive, may receive an unexpected force due to the magnetic field and perform a dangerous movement.　This medical instrument for MRI used in an MRI diagnosis room has a leg in which plate-shaped components are placed upright and combined to form a cylindrical space, a column inserted into the cylindrical space, a leg wedge inserted between the column and the cylindrical space in a direction perpendicular to the direction in which the column is inserted into the cylindrical space, and a head that is fixed to the column and that is constituted from a stage plate and a body obtained by combining plate-shaped components in a grid pattern. The leg, the column, the leg wedge, and the head are non-metallic and insulating bodies. The medical instrument for MRI does not exhibit magnetization not only caused by a magnetic field but also caused by an eddy current, and can therefore be used safely in a strong magnetic field.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

Provided is a manufacturing method of a novel fertilizer (for example, a liquid fertilizer) containing a decomposed bone tissue. A manufacturing method of a phosphoric acid-containing fertilizer according to one embodiment of the present invention includes at least one of the following step 1 (S7), step 2 (S2) and step 3 (S5). Step 1 (S7): A step for treating a bone tissue with a solution, which contains both an acid and a protease, and manufacturing a fertilizer from the resulting solubilized bone liquid A. Step 2 (S2): A step for treating a bone tissue with an acid and manufacturing a fertilizer from the resulting acid extract. Step 3 (S5): A step for treating an acid-treated bone tissue with a protease and manufacturing a fertilizer from the resulting protease-treated liquid.

IPC Classes  ?

• C05F 1/00 - Fertilisers made from animal corpses, or parts thereof
• C05G 5/20 - Liquid fertilisers

Abstract

Provided is a novel method for producing phosphoric acid. A method for producing phosphoric acid according to one embodiment of the present invention includes the following steps. (a) A step for treating a bone tissue with an acid to obtain an acid extract. (b) A step for adding a base to the obtained acid extract to obtain calcium phosphate thus precipitated. (c) A step for adding an acid to the obtained calcium phosphate precipitate to obtain a calcium phosphate solution. (d) A step for adding, to the obtained calcium phosphate solution, one or more selected from the group consisting of a sulfate, a carbonate and a hydrogencarbonate to remove calcium thus precipitated.

IPC Classes  ?

• C01B 25/22 - Preparation by reacting phosphate containing material with an acid, e.g. wet process
• C05F 1/00 - Fertilisers made from animal corpses, or parts thereof
• C05G 5/20 - Liquid fertilisers

Abstract

Provided is a novel method for producing a diarylacetylene derivative.　An alkyne derivative having aryl substituents at both ends is provided by subjecting a tetrahalogenated ethylene and phenylboronic acid to a cross-coupling reaction and then conducting a treatment with a base.

IPC Classes  ?

• C07C 5/00 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
• C07C 15/54 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part substituted by unsaturated hydrocarbon radicals polycyclic non-condensed containing a group with formula
• C07C 25/24 - Halogenated aromatic hydrocarbons with unsaturated side chains
• C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
• C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
• C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons

Abstract

Provided are a novel agent or composition and others. Provided are a novel agent or composition and others. The agent or composition comprises caryophyllene and is used for at least one selected from the following (purposes) (1) to (3) : (1) promoting relaxation, prolonging a resting-state time, and/or prolonging a motionless time, (2) promoting sleep, and (3) preventing blood pressure elevation. Provided are a novel agent or composition and others. The agent or composition comprises caryophyllene and is used for at least one selected from the following (purposes) (1) to (3) : (1) promoting relaxation, prolonging a resting-state time, and/or prolonging a motionless time, (2) promoting sleep, and (3) preventing blood pressure elevation. The present invention also relates to a method for inhaling β-caryophyllene simultaneously with smoking a tobacco product, characterized in that the tobacco product contains a β-caryophyllene-containing seamless capsule in a tobacco filter, wherein the seamless capsule contains an essential oil containing β-caryophyllene as an active ingredient. The applicants found that pulmonary inhalation of β-caryophyllene by the above method allows β-caryophyllene to be efficiently distributed throughout the body, leading to achievements of relaxing and sleep-inducing effects, etc.

IPC Classes  ?

• A24D 3/14 - Use of materials for tobacco smoke filters of organic materials as additive
• A24D 1/00 - CigarsCigarettes
• C11B 9/00 - Essential oilsPerfumes
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A61K 8/31 - Hydrocarbons
• A61Q 19/00 - Preparations for care of the skin
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/015 - Hydrocarbons carbocyclic

Abstract

As a solid biofuel serving as an alternative or mix-in for coal coke, there is demand for a solid biofuel that has a high combustion ratio and is capable of long-term combustion and of maintaining form during combustion.　This solid biofuel is obtained using a manufacturing method including: a first-stage step in which a raw material that has been chipped from a biomass resulting from photosynthesis is subjected to semi-carbonization to obtain a semi-carbonized raw material in which some of the moisture and volatile content of said raw material is released; and a second-stage step in which the semi-carbonized raw material is heated and pressed to obtain a consolidated molded article. Said solid biofuel has a fuel ratio exceeding 0.4 and a density of 1.0 g/cm322 reduction.

IPC Classes  ?

• C10L 5/44 - Solid fuels essentially based on materials of non-mineral origin on vegetable substances

Abstract

A first reference value that is a heart rate variability index of a normal person under a first auditory stimulus environment, a second reference value that is a heart rate variability index of the normal person under a second auditory stimulus environment that is different from the first auditory stimulus environment, a first comparative value that is a heart rate variability index of a user under the first auditory stimulus environment, and a second comparative value that is a heart rate variability index of the user under the second auditory stimulus environment are acquired. Comparison processing is performed among the first reference value, the second reference value, the first comparative value and the second comparative value to determine the possibility that a user has a mental disease.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval

Abstract

Heretofore, there has been no medicine or food medicament capable of preventing or ameliorating particularly a peripheral neuropathy induced by an anti-cancer agent such as oxaliplatin among adverse side effects induced by medication.　Provided is a prophylactic or ameliorating agent for a peripheral neuropathy, which comprises at least one compound selected from the compounds represented by formulae (1) to (3) as an active ingredient. The prophylactic or ameliorating agent can ameliorate numbness in the limbs, pain in the limbs, decreased deep tendon reflex, loss in muscle strength, allodynia, hyperalgesia, dysfunction in skilled movements of fingers, disturbance in gait, stumbling, falling, difficulties in bodily flexion (difficulties or inabilities associated with such postures as sitting on the soles, sitting with the legs crossed, sitting with the legs folded sideways, or sitting on a chair), limb paralysis or the like which are induced by drugs such as anticancer agents or induced by diabetes.　[Formula 200] [Formula 201] [Formula 202]

IPC Classes  ?

• C07C 69/003 - Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
• A61K 31/231 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

[Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect. [Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect. [Solution] A compound (I) contains a compound represented by a structural formula described below as an active ingredient, [Object] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect. [Solution] A compound (I) contains a compound represented by a structural formula described below as an active ingredient,

IPC Classes  ?

• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A61K 36/20 - Aceraceae (Maple family)
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

Conventional broadband light sources have had the problem of being difficult to oscillate or having an unstable oscillation state.　This optical fiber output light source device characterized by including: an optical path connecting a polarization-maintaining amplification optical fiber and a polarization-maintaining dispersion compensation optical fiber; a single-polarization reflective polarizing beam splitter connected to one end of the optical path; a 90° polarization rotation reflector connected to the other end of the optical path; a multiplexer inserted in the optical path; and an axial roll joining part that has an excitation light source connected to the multiplexer and connects, at a prescribed angle, the deviation angle of a polarization-maintaining axis of the optical path relative to a polarization axis of light returning to the optical path from the single-polarization reflective polarizing beam splitter. Reflected components can enter the single-polarization reflective polarizing beam splitter, thereby making oscillation easy and making it less likely that the oscillation state will be impacted by external disturbances.

IPC Classes  ?

• H01S 3/067 - Fibre lasers
• G02B 5/04 - Prisms
• G02B 5/08 - Mirrors
• G02F 1/35 - Non-linear optics
• G02F 1/383 - Non-linear optics for second-harmonic generation in an optical waveguide structure of the optical fibre type
• H01S 3/108 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity using non-linear optical devices, e.g. exhibiting Brillouin or Raman scattering

Abstract

In the reconstruction of a lost pinna, an implant-type regenerative medicine is performed. In this case, a skeletal structure using a bioabsorbable material has been proposed as a cell scaffold material. However, a skeletal structure that has strength, can be deformed easily, has restoring force, and is flexible has been still expected.　Provided is a skeletal structure (1) for an artificial pinna, which is characterized by comprising a planar base part (10) formed from a fibrous structure using a bioabsorbable material and a helix part (30) and an antihelix part (20) both provided on the surface of the base part (10). In the skeletal structure (1), a two-dimensional elastic structure is provided to the base part (10) and a three-dimensional fibrous structure formed from a fibrous structure is provided to each of the helix part (30) and the antihelix part (20). As a result, a flexible skeletal structure can be provided.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums

Abstract

The present invention addresses the problem of providing a method for efficiently producing α-tomatine. The method for producing α-tomatine that solves the problem includes a step for mixing at least one tomato plant body selected from the group consisting of tomato leaves, stems, auxiliary buds, immature fruits, and roots with an acidic solution and crushing the tomato plant bodies in the acidic solution to obtain an extract of α-tomatine. The pH of the extract is set at 4.5 or less.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically acceptable salt thereof, and a drug that is useful in the treatment of diseases caused by activation of T-type calcium channels.

IPC Classes  ?

• C07D 235/26 - Oxygen atoms
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/04 - Antipruritics
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

The present invention provides a compound of formula (I) wherein R1, R2, R3, R4, k, l, m and n are as defined in the specification, or a pharmaceutically acceptable salt thereof with the effect of inhibiting T-type calcium channels and a medicament useful for the treatment of a disease associated with the activation of T-type calcium channels.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/04 - Antipruritics
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/08 - AntiepilepticsAnticonvulsants
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/02 - Ophthalmic agents
• C07D 235/26 - Oxygen atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

To provide a novel T-type calcium channel blocker. To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker. To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker. wherein A represents a phenyl which may have a substituent, a 4-membered to 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, while here, the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to a nitrogen atom of the adjacent cyclic amino by means of a carbon atom constituting these rings; B represents a phenyl which may have a substituent, a 5-membered or 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, while here, the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to the adjacent cyclopropyl ring by means of a carbon atom constituting these rings; R1 and R2, which may be identical or different, each represent a hydrogen atom, a halogen atom, or the like; R3 represents a hydrogen atom, a halogen atom, or the like; n and m, which may be identical or different, each represent 0 or 1; and p represents 1 or 2.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• C07F 7/08 - Compounds having one or more C—Si linkages
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/113 - Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

A tamarind decomposition product which is a decomposition product of tamarind gum and has a weight-average molecular weight of 70,000 or less.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A61K 31/716 - Glucans
• A61K 36/48 - Fabaceae or Leguminosae (Pea or Legume family)CaesalpiniaceaeMimosaceaePapilionaceae
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression. An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. The problem, however, is the amount ingested to inhibit cancer cell growth is large.　A cancer cell growth inhibiting composition having a substance having a structure represented by formulas (1) through (6) as the main component has a cancer cell growth inhibiting effect one or more orders of magnitude greater than that of phytol. Like phytol, these substances are expected to have no effect on normal cells. Provision of an anticancer agent with few side effects can therefore be expected.

IPC Classes  ?

• A61K 31/131 - Amines, e.g. amantadine acyclic
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

33 or OH; and each of Y, Z, and W represents H or a monovalent organic group).

IPC Classes  ?

• C07C 323/58 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
• C07C 319/14 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides

Abstract

The type 1 MET tyrosine kinase inhibitors capmatinib and tepotinib are effective against lung cancer having an MET exon 14 skipping mutation and have been approved as first-line drugs in Japan and the US, but it is expected that resistance to both of these drugs will be acquired. However, there were no prospects for drugs that could be used next.　Lung cancer therapeutics having as an active ingredient any compound of formula (1) and formula (2) can overcome resistance to capmatinib and tepotinib and manifest an effect as an inhibitor against lung cancer having an MET exon 14 skipping mutation in which the amino acids 1228 and 1230 of c-MET are mutated to an amino acid other than aspartic acid and tyrosine, respectively.

IPC Classes  ?

• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• A61K 31/47 - QuinolinesIsoquinolines
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/00 - Antineoplastic agents

Abstract

COVID-19 caused by a coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome in a chimeric antigen receptor (CAR)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytotic syndrome, macrophage activation syndrome, influenza, GVHD, systemic vasculitis, Kawasaki disease, Takayasu's arteritis and the like cause acute respiratory distress syndrome, disseminated intravascular coagulation syndrome, acute circulatory failure, multiple organ failure or the like when being increased in severity, and are believed to be one of causes of death. This phenomenon is considered to be caused by cytokine storm.　Compounds represented by formulae (1) to (4) exert the effects thereof when administered orally, and can exert the effects thereof in smaller amounts than that of mangiferin.　[Formula 105] [Formula 106] [Formula 107] [Formula 108]

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61P 37/02 - Immunomodulators
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An object is to provide a cell culture scaffold which makes it possible to recover a cell culture product without being destroyed after cell culturing and a method for producing a cell culture product. An object is to provide a cell culture scaffold which makes it possible to recover a cell culture product without being destroyed after cell culturing and a method for producing a cell culture product. The cell culture scaffold according to the present invention includes a substrate having a water-repellent surface and a cell adhesion molecule formed on the water-repellent surface of the substrate. Further, the method for producing a cell culture product according to the present invention includes a step of culturing, using the cell culture scaffold, cells on the surface of the cell adhesion molecule. The cell culture scaffold according to the present invention makes it possible to recover the cells in a spheroid state without causing a damage.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

This bolus, which is for radiation therapy, can be deformed to match the shape of a human body surface, and has little deformation during therapy. The bolus forming material is a rubber composition containing ethylene-propylene rubber and a temperature-sensitive material. The bolus forming material has a JIS type A hardness of 20 or higher at 30°C, and thus is not susceptible to deformation. The bolus forming material has a JIS type E hardness of 10 to 60 at 70°C, and thus easily deforms. The bolus forming material shifts the peak of the percentage depth dose for electron beams and X-rays in the ray source direction at 0.8 to 1.2 times the thickness thereof. Therefore, the bolus forming material has dose characteristics in the depth direction that are substantially the same as a human body. After a sheet of the bolus forming material is heated to around 70°C, the sheet deforms so as to match the shape of the surface of a body of a patient. When this sheet is cooled, it is possible to obtain a bolus that closely adheres to the body of the patient. By interposing the bolus between the patient and an irradiation device, it is possible to adjust the dose characteristics in the depth direction.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Heretofore, there has been no medicine or food medicament capable of particularly preventing or improving, among side effects caused by medication, peripheral neuropathy caused by anticancer drugs such as oxaliplatin.　This agent for preventing or improving peripheral neuropathy contains, as an active ingredient, at least one selected from among xylitol, L-talitol, and D-threitol, and contributes to improving symptoms that are induced by medication such as anticancer drugs or induced by diabetes, and that include numbness in the limbs, pain in the limbs, decreased deep tendon reflex, loss in muscle strength, allodynia, hyperalgesia, dysfunction in skilled movements of fingers, disturbance in gait, stumbling, falling, difficulties in bodily flexion (difficulties or inabilities associated with such postures as sitting on the soles, sitting with the legs crossed, sitting with the legs folded sideways, or sitting on a chair), or limb paralysis.

IPC Classes  ?

• A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A61K 31/282 - Platinum compounds
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61P 17/04 - Antipruritics

Abstract

Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK.　Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

IPC Classes  ?

• C07D 311/86 - Oxygen atoms, e.g. xanthones
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

There are societal demands during times of emergency and the like for a bed that has few components and is easy to assemble, is strong and lightweight, and has excellent heat retaining properties and water resistance, and the present invention proposes a bed with which these requirements can be achieved in a well-balanced manner. An easy-assembly bed (1) includes a top plate (10), and leg portions (30) in which a plurality of leg members (20) are linked using notched joints, wherein: the top plate (10) is configured from a bonded material comprising a plate-shaped foam plate (42) formed from a foam body, and a front board member and a rear board member having the same shape as the foam plate, which are bonded to the rear surface and the front surface of the foam plate (42), and a top plate molded resin portion obtained by covering the cut ends of the bonded material with molded resin; and the leg members (20) are each configured from a grooved bonded material including a plate-shaped grooved foam plate which has latching grooves and which is formed from a foam body, and, on the front surface and the rear surface of the grooved foam plate, a grooved front board member and a grooved rear board member having the same shape as the grooved foam plate, and a leg member molded resin portion obtained by covering the cut ends of the grooved bonded material with molded resin.

IPC Classes  ?

• A47B 37/00 - Tables adapted for other particular purposes
• A47C 17/64 - Travelling or camp beds
• A47C 19/00 - Bedsteads

Abstract

An aortic aneurysm does not have many noticeable symptoms, and the risk of rupturing while still unnoticed is high. Further, when rupturing occurs, a patient enters a shock state due to massive bleeding, and the rate of survival is extremely low. Consequently, when an aortic aneurysm is discovered in a medical examination or the like, depending on the stage of progression, it has been necessary to carry out a surgery such as a stent-graft.　This pharmaceutical composition for prevention and treatment of an aortic aneurysm, which has a medium chain fatty acid as a main component thereof, has the effect of inhibiting the development and progression of an aortic aneurysm; thus, when an aortic aneurysm is discovered, by continued use of the pharmaceutical composition, it is possible to not just inhibit the progression of the aortic aneurysm, but also to cause regression of the aortic aneurysm, and it is possible to exhibit the effect of improving life prognosis.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A23L 33/12 - Fatty acids or derivatives thereof
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Provided are a therapeutic agent for short tear breakup time (TBUT)–type dry eye, which has excellent therapeutic effect on dry eye and high safety, and eye drops containing the therapeutic agent.　The present inventors found that a therapeutic agent for short TBUT-type dry eye, said therapeutic agent comprising a copolymer which has three different structural units at a specific ratio and water, is efficacious for treating dry eye, because this therapeutic agent sufficiently moisturizes the corneal surface and retains water thereon so as to induce mucin production on the corneal surface, thereby completing the invention.

IPC Classes  ?

• A61K 31/80 - Polymers containing hetero atoms not provided for in groups
• A61K 9/08 - Solutions
• A61P 27/02 - Ophthalmic agents

Abstract

Eyedrops for ameliorating retinal circulatory disturbance and disorders associated with retinal nerve blood vessels, which contains fibrate-containing nanoparticles.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 9/10 - DispersionsEmulsions
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61P 27/02 - Ophthalmic agents

Abstract

A composition for treating a vascular disease, for preventing a vascular disease, for treating hypertension or for preventing hypertension, which contains caryophyllene.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/31 - Hydrocarbons
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61Q 19/00 - Preparations for care of the skin

Abstract

Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhibition is large. A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.

IPC Classes  ?

• C07C 233/09 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
• A23L 33/175 - Amino acids
• A61P 35/00 - Antineoplastic agents
• C07C 211/21 - Monoamines
• C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Abstract

The present invention provides a collagen solid having higher strength and density. A collagen solid is used which contains a collagen-cysteine protease degradation product or an atelocollagen-cysteine protease degradation product and has a density of 50 mg/cm3 or more.

IPC Classes  ?

• A61L 27/24 - Collagen
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Abstract

This nerve regeneration inducing tube cutting tool (1) comprises: a base member (10); a nerve regeneration inducing tube mounting groove (12) into which a nerve regeneration inducing tube (100) is to be mounted, the groove being provided so as to extend in a first direction and recessed from a surface (15) of the base member (10); and a guide groove (14) that guides the passage of a cutting knife for cutting the nerve regeneration inducing tube (100), the guide groove extending in a second direction orthogonal to the first direction in which the nerve regeneration inducing tube mounting groove (12) extends and traversing the nerve regeneration inducing tube mounting groove (12), a plurality of guide grooves (14) being provided along the first direction. With this nerve regeneration inducing tube cutting tool, the work of cutting the nerve regeneration inducing tube to a prescribed length can easily be accomplished accurately and quickly.

IPC Classes  ?

• B26D 3/16 - Cutting rods or tubes transversely
• B26D 7/01 - Means for holding or positioning work
• B26D 7/20 - Cutting beds

Abstract

A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, n represents 0 or 1.

IPC Classes  ?

• C07D 235/16 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

According to a conventional method for determining a resonance frequency, vibration of an implant or the like is caused using light, and the state of the vibration is subjected to frequency analysis. However, the method requires the use of a strong light source, and therefore imposes a lot of burden when used.　This installation strength measurement device is characterized by comprising: a vibration-causing light generator for irradiating a measurement object with light having varying intensity; a vibration measuring instrument for measuring at least the vibration intensity of the measurement object between the vibration frequency and vibration intensity of the measurement object; and a controller for obtaining information pertaining to the installation strength of the measurement object by causing the vibration-causing light generator to irradiate the measurement object with the light at a plurality of irradiation cycles, obtaining the amplitude intensity from the vibration measuring instrument at each irradiation cycle, and selecting a vibration frequency providing the highest vibration intensity. The installation strength measurement device is usable without any restriction and imposes least burden on a user, because the installation strength measurement device determines the resonance frequency of a fixed object using weak light.

IPC Classes  ?

• A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools
• A61C 19/04 - Measuring instruments specially adapted for dentistry

Abstract

Provided are a novel agent or composition, etc.　The agent or composition contains caryophyllene and is used for at least one (purpose) selected from (1)-(3) below. (1) Promotion of a relaxing effect, prolongation of rest time and/or prolongation of quiescent time. (2) Sleep promotion. (3) Suppression of blood pressure elevation. The present invention also pertains to a method for filling a seamless capsule with an essential oil having β-caryophyllene as an active ingredient and mounting the capsule on a cigarette filter, whereby the β-caryophyllene is inhaled simultaneously with smoking. The applicant discovered that by inhaling β-caryophyllene through the lungs by the above method, β-caryophyllene is efficiently distributed throughout the body, leading to a relaxing effect, a sleep-inducing effect, etc.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A24D 1/00 - CigarsCigarettes
• A24D 3/14 - Use of materials for tobacco smoke filters of organic materials as additive
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61P 9/12 - Antihypertensives
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/20 - HypnoticsSedatives
• A61Q 13/00 - Formulations or additives for perfume preparations
• C11B 9/00 - Essential oilsPerfumes

Abstract

No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin. Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.

IPC Classes  ?

• A61K 36/07 - Basidiomycota, e.g. Cryptococcus
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 35/00 - Antineoplastic agents
• A61K 33/243 - PlatinumCompounds thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
• A61K 31/4965 - Non-condensed pyrazines

Abstract

To improve the fact that the main components of conventional deodorizing and antimicrobial agents are existing components, the effect and efficacy of which are known to some extent, and do not generate an effect better than predicted. The deodorizing and antimicrobial agent of the present invention has a loquat seed extract including non-volatile fatty acids and at least benzaldehyde and benzoic acid as a main raw material.

IPC Classes  ?

• A01N 65/34 - Rosaceae [Rose family], e.g. strawberry, hawthorn, plum, cherry, peach, apricot or almond
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61L 9/013 - Deodorant compositions containing animal or plant extracts, or vegetable material
• A01N 35/04 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio-analogues thereof, directly attached to an aromatic ring system, e.g. acetophenoneDerivatives thereof, e.g. acetals
• A01N 65/08 - Magnoliopsida [dicotyledons]
• A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
• A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereofDerivatives thereof
• A61L 9/01 - Deodorant compositions
• A61L 101/36 - Carboxylic acids or derivatives thereof

Abstract

[Problem] To provide a composition having an excellent α-glucosidase inhibitory effect or invertase inhibitory effect. [Solution] Compound (I) which comprises a compound represented by a structural formula as an active ingredient.

IPC Classes  ?

• A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 36/20 - Aceraceae (Maple family)
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/99 - Enzyme inactivation by chemical treatment